Ureteric cancer, also called ureteral cancer, is a rare cancer that develops in the ureter, the tube that carries urine from the kidney to the bladder. Most cancers of the ureter are urothelial carcinomas, which develop from the cells lining the urinary tract.
Treatment depends on the location, grade and extent of the tumor, kidney function, whether the disease has spread and the patient's overall health. A detailed urological evaluation is important for selecting an appropriate treatment approach.
The ureters are narrow muscular tubes that transport urine from each kidney to the urinary bladder. Ureteric cancer occurs when abnormal cells in the lining of the ureter grow uncontrollably and form a tumor.
Most ureteric cancers are urothelial carcinomas. These cancers are part of a group known as upper tract urothelial carcinoma because they arise in the renal pelvis or ureter rather than the bladder.
The type of ureteric cancer is determined by the cells from which the tumor develops. Urothelial carcinoma is the most common type.
The most common type of cancer affecting the lining of the ureter. It is also known as transitional cell carcinoma.
A less common type that may be associated with chronic irritation, infection or stone-related conditions.
A rare type of ureteric cancer that develops from glandular-type cells.
Having a risk factor does not mean that a person will develop ureteric cancer. Some patients may develop the disease without an identifiable risk factor.
Risk factors only indicate an increased possibility of developing disease. They cannot by themselves diagnose ureteric cancer.
Ureteric cancer may not cause obvious symptoms in its early stages. When symptoms occur, they may vary according to the location and extent of the tumor.
Hematuria may appear as visibly red or pink urine or may only be detected during urine testing.
A tumor may cause pain in the side or back, particularly when it affects urine drainage.
Some patients may experience painful urination, increased frequency or urinary urgency.
Unexplained fatigue or weight loss may occur, particularly in more advanced disease.
Blood in the urine should not be ignored, even when there is no pain. Hematuria can have many causes, but persistent or unexplained blood in the urine requires appropriate medical evaluation.
Blood in the urine does not necessarily mean cancer, but it should be evaluated to identify the underlying cause.
Diagnosis involves evaluating the urinary tract, identifying any abnormal growth and determining the characteristics and extent of the disease. The exact investigations depend on the patient's symptoms, medical history and clinical findings.
Urine testing can identify blood and other abnormalities that may require further investigation.
A urine sample may be examined for abnormal cells shed from the urinary tract.
Detailed imaging can help evaluate the kidneys, ureters and surrounding structures.
A thin scope can be passed through the urinary tract to directly examine the ureter and obtain tissue when required.
When tissue is obtained during ureteroscopy or surgery, pathological examination helps determine the type and grade of the tumor. The findings are considered together with imaging and other clinical information when planning treatment.
Staging describes how far the cancer has developed or spread. Ureteric cancer is generally evaluated using the TNM staging system, which considers the primary tumor, nearby lymph nodes and distant spread.
The stage, tumor grade, location, kidney function and other clinical factors help the cancer care team determine the most appropriate treatment strategy.
Treatment is individualized and may involve surgery, endoscopic treatment, systemic therapy or a combination of treatments depending on the stage and characteristics of the cancer.
Removal of the kidney, entire ureter and a portion of the bladder around the ureteric opening may be recommended for selected higher-risk or invasive tumors.
In carefully selected patients, the affected portion of the ureter may be removed while preserving the remaining kidney and ureter.
Selected small, localized and appropriate tumors may be treated through ureteroscopic techniques.
Depending on the stage and clinical situation, chemotherapy or other systemic cancer treatments may be considered by the oncology team.
Not every ureteric cancer requires the same treatment. Tumor location, grade, stage, kidney function, previous cancer history and overall health all influence the treatment plan.
Surgery is an important treatment option for localized ureteric cancer. The surgical approach depends on the tumor's location, risk features, extent and the need to preserve kidney function where appropriate.
Imaging, urine tests, pathology and assessment of kidney function are reviewed before treatment.
The location and extent of the tumor are assessed to determine whether kidney-sparing surgery or nephroureterectomy is appropriate.
The cancerous segment or the kidney and ureter may be removed according to the selected surgical approach.
The removed tissue is examined to determine tumor type, grade, margins and pathological stage.
Further surveillance and treatment are planned according to the pathology and overall cancer assessment.
Preparation depends on the planned procedure and the patient's general health. Your urologist and surgical team will provide individualized instructions.
Recovery depends on the type of surgery, the extent of the cancer, the patient's general health and whether additional treatment is required. Your surgeon will provide individualized postoperative instructions.
Patients may be monitored for pain, urine output, bleeding, infection and kidney function.
Walking and daily activities are gradually resumed according to the surgeon's instructions.
Final pathology helps determine whether additional cancer treatment or closer surveillance is required.
Regular follow-up is important because urothelial cancers can recur and may require ongoing urinary tract surveillance.
Treatment aims to remove or control the cancer according to its stage and biological characteristics.
The surgical approach is selected according to tumor location, extent and individual patient factors.
In selected patients, treatment planning may consider preservation of kidney function where clinically appropriate.
Follow-up helps detect recurrence or other urinary tract disease at an early stage.
The risks depend on the type of procedure, the extent of disease and the patient's overall health. Your surgeon will discuss procedure-specific risks before treatment.
After surgery, contact your treating team promptly if you develop high fever, severe or increasing pain, significant bleeding, difficulty passing urine, persistent vomiting or other concerning symptoms.
The outcome of ureteric cancer depends on several factors, particularly the depth of tumor invasion, tumor grade, lymph-node involvement, distant spread and the patient's overall health.
Treatment planning and follow-up are therefore individualized. The pathology report and staging investigations provide important information for determining the next steps after diagnosis or surgery.
Urothelial cancers can recur in the urinary tract. Your urologist may recommend periodic urine tests, imaging, cystoscopy or other investigations based on your individual risk and treatment history.
The cost of ureteric cancer treatment varies significantly because the treatment plan depends on the type and stage of cancer and the procedure required.
A personalized estimate can be discussed after reviewing the clinical findings, imaging, pathology and proposed treatment plan.
Ureteric cancer is a cancer that develops in the ureter, the tube that carries urine from the kidney to the bladder. Most cases are urothelial carcinomas.
Blood in the urine is an important symptom. Other possible symptoms include flank or back pain, urinary symptoms, fatigue and unexplained weight loss.
No. Blood in the urine can have several causes, including stones, infections and other urinary conditions. However, unexplained hematuria should be medically evaluated.
Evaluation may include urine tests, urine cytology, CT urography or other imaging, ureteroscopy and biopsy when appropriate.
Urothelial carcinoma is the most common type of cancer affecting the ureter.
Treatment depends on the cancer's location, grade and stage. Options may include surgery, selected endoscopic treatments and systemic cancer treatment.
Not necessarily in every patient. Nephroureterectomy may be recommended for selected higher-risk tumors, while kidney-sparing approaches may be appropriate in carefully selected cases.
Selected low-risk or localized tumors may be considered for endoscopic treatment. Suitability depends on tumor characteristics and the patient's individual circumstances.
Staging determines how far the cancer has developed or spread. Ureteric cancer is evaluated using factors including the primary tumor, lymph nodes and distant metastasis.
Yes. Urothelial cancers can recur, which is why regular follow-up and surveillance are important after treatment.
Smoking is a recognized risk factor for urothelial cancers, including cancers affecting the upper urinary tract.
Consult a urologist if you notice unexplained blood in the urine, persistent urinary symptoms, unexplained flank pain or other concerning urinary symptoms.
Dr. Yash R. Godbole is a Consultant Urologist & Andrologist providing evaluation and surgical management for urinary tract conditions, including complex urological problems requiring individualized treatment planning.
Consult Dr. Yash R. Godbole for evaluation of ureteric cancer, discussion of diagnostic findings and individualized treatment options.
Medical Disclaimer: The information provided on this page is for general educational purposes only and should not be considered a substitute for professional medical advice, diagnosis or treatment. Ureteric cancer treatment depends on individual clinical findings, pathology, imaging, cancer stage, kidney function and overall health. Please consult a qualified urologist for personalized medical advice.